Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 125096-73-3 | MDL No. : | MFCD09954865 |
Formula : | C8H4ClIN2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | JMEUDFPLOIQUOL-UHFFFAOYSA-N |
M.W : | 290.49 | Pubchem ID : | 14397531 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 10 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 57.27 |
TPSA : | 25.78 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.84 cm/s |
Log Po/w (iLOGP) : | 2.23 |
Log Po/w (XLOGP3) : | 3.15 |
Log Po/w (WLOGP) : | 2.89 |
Log Po/w (MLOGP) : | 2.72 |
Log Po/w (SILICOS-IT) : | 3.54 |
Consensus Log Po/w : | 2.91 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -4.24 |
Solubility : | 0.0166 mg/ml ; 0.0000573 mol/l |
Class : | Moderately soluble |
Log S (Ali) : | -3.36 |
Solubility : | 0.126 mg/ml ; 0.000435 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.89 |
Solubility : | 0.00377 mg/ml ; 0.000013 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 1.95 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
70% | In pyridine for 4h; Heating; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
55% | In pyridine for 4h; Heating; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
70% | In pyridine for 4h; Heating; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
45% | In pyridine for 4h; Heating; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
34.8 g | Stage #1: 8-iodoquinazolin-4(1H)-one With trichlorophosphate for 8h; Reflux; Stage #2: With dihydrogen peroxide In lithium hydroxide monohydrate | 2 Comparative Example 2 Tosylic acid dihydrate (0.038 g) was added to a suspension of 2-amino-3-iodobenzamide (0.513 g) supplemented with methyl orthoformate (5 ml) and NMP (1 ml), and the mixture was heated to reflux for 3 hours. After cooling, water was added to the reaction solution, and the deposit was filtrated and dried under reduced pressure to obtain 8-iodoquinazolin-4(1H)-one (0.481 g). Phosphorus oxychloride (10 ml) was added to the obtained 8-iodoquinazolin-4(1H)-one (1.17 g), and the mixture was heated to reflux for 8 hours. The solvent was distilled off under reduced pressure, and chloroform was added to the residue. The reaction solution was neutralized with an aqueous sodium hydroxide solution with cooling in an ice bath and partitioned into organic and aqueous layers. The organic layer was washed with brine. The organic layer thus washed was dried over anhydrous sodium sulfate. Then, the solvent was distilled off, and the residue was purified by neutral silica gel column chromatography (chloroform/ethyl acetate) to obtain 4-chloro-8-iodoquinazoline (0.946 g). 4-(4-Chloroquinazolin-8-yl)-2-(4-hydroxycyclohexylamino)benzonitrile was obtained according to Example 2(1) using the obtained 4-chloro-8-iodoquinazoline instead of compound (1b) and PdCl2dppf instead of Pd(PPh3)4. A compound of Comparative Example 2 was obtained as a pale yellow solid (yield based on 5 steps: 10%) according to Example 79 using the obtained 4-(4-chloroquinazolin-8-yl)-2-(4-hydroxycyclohexylamino)benzonitrile instead of compound (4b) and 3-quinolineboronic acid instead of 3-(tert-butylamino)-4-cyanophenylboronic acid pinacol ester. |
With dichlorosulfoxide In N,N-dimethyl-formamide at 90℃; for 14h; | 6.3 third step Compound 6-3 (370 mg, 1.36 mmol) was added to N,N-dimethylformamide (0.1 mL), then thionyl chloride (4 mL) was added, and the reaction solution was stirred at 90 degrees Celsius for 14 hours.The reaction solution was cooled to room temperature and concentrated under reduced pressure.Toluene (20 mL) was added to the residue obtained by concentration under reduced pressure, and the mixture was washed once with saturated sodium bicarbonate (20 mL).The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude compound 6-4. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: toluene-4-sulfonic acid / 1-methyl-pyrrolidin-2-one / 3 h / Reflux 2: trichlorophosphate / 8 h / Reflux | ||
Multi-step reaction with 2 steps 1: toluene-4-sulfonic acid / 1-methyl-pyrrolidin-2-one / 12 h / 110 °C 2: dichlorosulfoxide / N,N-dimethyl-formamide / 14 h / 90 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With anhydrous sodium carbonate In isopropanol at 60℃; for 15h; | 6.4 the fourth step Compound 6-4 (220 mg, 757 μmol) and Intermediate B (205 mg, 757 μmol) were dissolved in isopropanol (5 mL) and sodium carbonate (161 mg, 1.51 mmol) was added.The reaction solution was stirred at 60 degrees Celsius for 15 hours.The reaction solution was concentrated under reduced pressure, and the obtained crude product was separated and purified by column chromatography (eluent: petroleum ether/ethyl acetate, 10/14/1, V/V) to obtain compound 6-5. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: anhydrous sodium carbonate / isopropanol / 15 h / 60 °C 2: dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II) dichloromethane adduct; tripotassium phosphate tribasic / lithium hydroxide monohydrate; N,N-dimethyl-formamide / 16 h / 85 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 3 steps 1: anhydrous sodium carbonate / isopropanol / 15 h / 60 °C 2: dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II) dichloromethane adduct; tripotassium phosphate tribasic / lithium hydroxide monohydrate; N,N-dimethyl-formamide / 16 h / 85 °C 3: hydrogenchloride / ethyl acetate / 0.67 h / 20 °C |
[ 98436-53-4 ]
4-Chloro-6,8-diiodoquinazoline
Similarity: 0.98
[ 959237-40-2 ]
2,4-Dichloro-8-iodoquinazoline
Similarity: 0.92
[ 1222373-90-1 ]
5-Chloro-8-iodopyrido[4,3-d]pyrimidine
Similarity: 0.90
[ 98436-53-4 ]
4-Chloro-6,8-diiodoquinazoline
Similarity: 0.98
[ 959237-40-2 ]
2,4-Dichloro-8-iodoquinazoline
Similarity: 0.92
[ 1222373-90-1 ]
5-Chloro-8-iodopyrido[4,3-d]pyrimidine
Similarity: 0.90
[ 98436-53-4 ]
4-Chloro-6,8-diiodoquinazoline
Similarity: 0.98
[ 959237-40-2 ]
2,4-Dichloro-8-iodoquinazoline
Similarity: 0.92